|Slideshows|September 27, 2017

8 Reasons a Psychotropic Medication May Be Discontinued

Tips for having a balanced and comprehensive risk-to-benefit discussion with competent patients who want to stop their medications.

This article was originally posted on January 28, 2015 and has since been updated.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Helping Patients Navigate the Halloween Season and Sensory Overload: In Conversation With Richard W. Miller, MD

ByLeah Kuntz,Richard W. Miller, MD

October 31st 2025

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, MD

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, PhD

ByMaciej Wieczorek, PhD

October 27th 2025

A Critical Catch: Catatonia Due to Multiple General Medical Conditions

ByErica Taylor, MD, MPH,Drew Cumming, MD,James A. Bourgeois, OD, MD

October 24th 2025

Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder

ByLeah Kuntz

October 23rd 2025

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

ByJessica Walters

October 23rd 2025

Latest CME

Video

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

8 Reasons a Psychotropic Medication May Be Discontinued

Newsletter

Related Content

Helping Patients Navigate the Halloween Season and Sensory Overload: In Conversation With Richard W. Miller, MD

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, PhD

A Critical Catch: Catatonia Due to Multiple General Medical Conditions

Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

Latest CME

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Survival Guide For Human Therapists In A Chatbot World

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach

sNDA Submitted for AXS-05 for the Treatment of Alzheimer Disease Agitation

Deciding How to Try to Make This a Better World

Poll: Has the Shortage of IV Ativan Impacted Your Practice?